Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Modafinil
Drug ID BADD_D01484
Description Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA.
Indications and Usage To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
Marketing Status approved; investigational
ATC Code N06BA07
DrugBank ID DB00745
KEGG ID D01832
MeSH ID D000077408
PubChem ID 4236
TTD Drug ID D07HQC
NDC Product Code 46438-0655; 63285-000; 63552-066; 70771-1051; 71205-477; 46438-0102; 65862-602; 60505-2526; 65862-601; 68071-2844; 69452-343; 65129-1102; 71205-544; 71335-1096; 63459-201; 68084-721; 70771-1052; 71335-1402; 72578-006; 63459-101; 23155-604; 71335-1793; 71610-685; 71335-1122; 72578-005; 50268-571; 55253-801; 57237-155; 60505-2527; 62332-385; 69452-342; 71335-1173; 0904-6423; 58175-0378; 63552-067; 23155-605; 46708-385; 55253-802; 63285-001; 46708-386; 63629-7315; 68084-621; 68788-7432; 68788-8280; 0904-6424; 0904-6791; 0904-6792; 72761-023; 42043-161; 50268-570; 57237-154; 62332-386; 63629-4998; 68788-8079; 63415-0036; 65862-576; 42043-160; 43353-925
UNII R3UK8X3U3D
Synonyms Modafinil | 2-((Diphenylmethyl)sulfinyl)acetamide | Vigil | Sparlon | Nuvigil | Alertec | Benzhydrylsulfinylacetamide | Armodafinil | 2-((R)-(Diphenylmethyl)sulfinyl)acetamide | R-Modafinil | R Modafinil | Provigil | Modiodal | CRL 40476 | CRL-40476
Chemical Information
Molecular Formula C15H15NO2S
CAS Registry Number 68693-11-8
SMILES C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.000823%
Abnormal dreams19.02.03.001; 17.15.02.0010.000617%Not Available
Abortion spontaneous18.01.04.0010.000906%Not Available
Aggression19.05.01.0010.001729%Not Available
Agitation19.06.02.001; 17.02.05.0120.002717%
Agranulocytosis01.02.03.001--Not Available
Albuminuria20.02.01.001--Not Available
Alcoholism19.07.06.0060.000617%Not Available
Amblyopia06.02.01.001--Not Available
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000617%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.0020.003457%
Arrhythmia02.03.02.0010.001029%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Ataxia17.02.02.001; 08.01.02.0040.000412%
Atrial fibrillation02.03.03.0020.000617%
Back pain15.03.04.005--
Bladder pain20.02.02.001--Not Available
Blood pressure increased13.14.03.005--Not Available
Body temperature decreased13.15.01.010--Not Available
Body temperature increased13.15.01.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages